Text Size

Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (SPORE)

This study is currently recruiting participants.
Verified March 2013 by University of Alabama at Birmingham
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Charles Mel Wilcox, MD, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00584363
First received: December 24, 2007
Last updated: March 13, 2013
Last verified: March 2013
History of Changes
  Purpose

The purpose of the study is to collect pancreatic tissue, blood and urine from adults to study pancreatic abnormalities.


Condition
Pancreatic Cancer

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic Cancer)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • To diagnose Pancreatic Cancer [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Preventing patient form being misdiagnosed [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Specimens are frozen and stored


Estimated Enrollment: 600
Study Start Date: June 2004
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Detailed Description:

The aim of the study is to standardize, collect and share pancreatic cancer related information, to be used for research purposes only by researchers from different participating institutions/centers.

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adults 19 years of age or older, pancreatic cancer patients at the University of Alabam at Birmingham.

Criteria

Inclusion Criteria:

  • Person over 19 years of age, patient with a tissue-proven diagnosis of pancreatic cancer at the University of Alabama at Birmingham (UAB) University Hospital during the period, and cognitive ability to provide informed consent

Exclusion Criteria:

  • Person not 19 or older and have not had a tissue-proven diagnosis of pancreatic cancer.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00584363

Contacts
Contact: Stacey Branham, RN, BSN (205) 975-9564 sbranham@uab.edu
Contact: Toni Seay, M.A. (205) 934-7332 tamartin@uab.edu

Locations
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
Charles Mel Wilcox, MD
National Cancer Institute (NCI)
Investigators
Principal Investigator: Charles M Wilcox, MD University of Alabama at Birmingham
  More Information

No publications provided

Responsible Party: Charles Mel Wilcox, MD, Principal Investigator, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00584363     History of Changes
Other Study ID Numbers: F040514008, #000185970, 2P50CA101955
Study First Received: December 24, 2007
Last Updated: March 13, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Digestive System Neoplasms
Gastrointestinal Neoplasms
Pancreatic Neoplasms
Neoplasms by Site
Neoplasms
 Digestive System Diseases
Gastrointestinal Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 16, 2013